Masonry
PAMIX 130
Admixture for masonry concrete
Translated from the Spanish data sheet. Standard designations, ASTM type numbers, figures and units are reproduced unchanged; in case of doubt the Spanish PDF governs.
Description
Pamix 130 is a liquid admixture for use in the manufacture of zero-slump masonry products (dry-cast concrete), improving cement hydration.
Recommended applications
- Concrete blocks.
- Pavers.
- Segmental retaining wall units.
- Concrete roof tiles.
- Dry-cast concrete pipe.
- Precast slabs.
Advantages
- Increases the production rate.
- Increased compressive and flexural strength.
- Reduces breakage and waste.
- Reduction in the amount of cement used.
- Extends the life of the moulds and machinery parts.
- Overall increase in profitability.
Dosage
Reference dosage 180 - 500 ml/100 kg of cementitious material
The recommended dosage is in the range of 180 - 500 ml/100 kg of cementitious material.
Mixing: Add Pamix 130 to the mix after the materials (cement and aggregates) have been mixed with at least 80% of the mixing water. Mix for at least one and a half minutes.
The best performance of the admixture in the concrete mix is obtained by evaluating the materials to be used; by keeping to this practice with the guidance of PAMIX INTERNATIONAL, S.A., you will obtain the best cost–benefit ratio.
Compatibility
Pamix 130 is effective either as a single admixture or as part of a system with other admixtures in the Pamix line; it is added to the mix independently of other admixtures
Packaging
Pamix 130 is supplied in bulk, in 200 L drums and in 1000 litre containers.
The admixture should be kept closed and sealed at all times in its original containers, in a roofed store protected from the weather
Shelf life
12 months in the original unopened container.
Standards and compliance
- ASTMC 494
- ASTM C260
Data sheet version 2. The PDF is the reference document. Warranty →
Documentation
Support
The laboratory reviews your mix design, proposes dosage and, if needed, modifies it to the customer’s requirement.
Talk to the lab →